Table 3.
List of significantly modulated canonical pathways in tears of hard and soft CL users.
| Canonical Pathways | −log (P-value) | Molecules |
|---|---|---|
| Hard A vs . CTRL | ||
| Glycolysis I | 8.31 | GPI, TPI1, PKM, GAPDH, FBP1 |
| Gluconeogenesis I | 6.31 | GPI, GAPDH, FBP1, MDH1 |
| FXR/RXR activation | 3.57 | C3, TF, FBP1, A1BG |
| Aryl hydrocarbon receptor signaling | 3.39 | TGM2, ALDH1A1, GSTP1, HSPB1 |
| Phagosome maturation | 3.3 | PRDX1, PRDX5, CTSB, PRDX6 |
| Methylglyoxal degradation III | 3.15 | AKR1A1, AKR1C1/AKR1C2 |
| NRF2-mediated oxidative stress response | 2.87 | AKR1A1, PRDX1, TXN, GSTP1 |
| Soft A vs . CTRL | ||
| LXR/RXR activation | 21.2 | TTR, C3, APOH, VTN, SERPINF1, ALB, LYZ, APOA1, TF, ORM1, ORM2, SERPINA1, GC, CLU, RBP4, AGT, TTR, C3, APOH, VTN, SERPINF1, ALB, APOA1, TF, ORM1, FBP1, |
| FXR/RXR activation | 20.9 | ORM2, SERPINA1, GC, CLU, RBP4, AGT |
| Acute phase response signaling | 18.8 | TTR, C3, APOH, SERPINF1, SERPINA3, ALB, HP, APOA1, ITIH2, TF, ORM1, ORM2, SERPINA1, A2M, RBP4, AGT |
| Glycolysis I | 11.8 | PGK1, ENO1, GPI, TPI1, PKM, GAPDH, FBP1 |
| Clathrin-mediated endocytosis signaling | 10.4 | ALB, LYZ, APOA1, ORM1, TF, UBA52, ORM2, SERPINA1, ACTG1, CLU, RBP4 |
| Atherosclerosis signaling | 8.11 | ALB, LYZ, APOA1, ORM1, ORM2, SERPINA1, CLU, RBP4 |
| Gluconeogenesis I | 7.72 | PGK1, ENO1, GPI, GAPDH, FBP1 |